137 related articles for article (PubMed ID: 36585434)
21. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.
van Gils MP; Hessels D; van Hooij O; Jannink SA; Peelen WP; Hanssen SL; Witjes JA; Cornel EB; Karthaus HF; Smits GA; Dijkman GA; Mulders PF; Schalken JA
Clin Cancer Res; 2007 Feb; 13(3):939-43. PubMed ID: 17289888
[TBL] [Abstract][Full Text] [Related]
22. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
[TBL] [Abstract][Full Text] [Related]
23. Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect.
Perlis N; Al-Kasab T; Ahmad A; Goldberg E; Fadak K; Sayyid R; Finelli A; Kulkarni G; Hamilton R; Zlotta A; Ghai S; Fleshner N
J Urol; 2018 May; 199(5):1182-1187. PubMed ID: 29175542
[TBL] [Abstract][Full Text] [Related]
24. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.
Wu AK; Reese AC; Cooperberg MR; Sadetsky N; Shinohara K
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):100-5. PubMed ID: 22042252
[TBL] [Abstract][Full Text] [Related]
25. Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy.
Feibus AH; Sartor O; Moparty K; Chagin K; Kattan MW; Ledet E; Levy J; Lee B; Thomas R; Silberstein JL
J Urol; 2016 Oct; 196(4):1053-60. PubMed ID: 27140073
[TBL] [Abstract][Full Text] [Related]
26. Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice.
Lebastchi AH; Russell CM; Niknafs YS; Eyrich NW; Chopra Z; Botbyl R; Kabeer R; Osawa T; Siddiqui J; Siddiqui R; Davenport MS; Mehra R; Tomlins SA; Kunju LP; Chinnaiyan AM; Wei JT; Tosoian JJ; Morgan TM
Urology; 2020 Nov; 145():204-210. PubMed ID: 32777370
[TBL] [Abstract][Full Text] [Related]
27. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol.
Pepe P; Aragona F
Can J Urol; 2013 Feb; 20(1):6620-4. PubMed ID: 23433132
[TBL] [Abstract][Full Text] [Related]
29. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
[TBL] [Abstract][Full Text] [Related]
30. [The role of a single PCA3 test before a first negative prostate biopsy: 5-year follow-up].
Bernardeau S; Charles T; Fromont-Hankard G; Irani J
Prog Urol; 2017 Apr; 27(5):325-330. PubMed ID: 28385586
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy.
Bollito E; De Luca S; Cicilano M; Passera R; Grande S; Maccagnano C; Cappia S; Milillo A; Montorsi F; Scarpa RM; Papotti M; Randone DF
Anal Quant Cytol Histol; 2012 Apr; 34(2):96-104. PubMed ID: 22611765
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies.
Trock BJ; Brotzman MJ; Mangold LA; Bigley JW; Epstein JI; McLeod D; Klein EA; Jones JS; Wang S; McAskill T; Mehrotra J; Raghavan B; Partin AW
BJU Int; 2012 Jul; 110(1):56-62. PubMed ID: 22077694
[TBL] [Abstract][Full Text] [Related]
33. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of PCA3 and multiparametric MRI's: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL.
Okcelik S; Soydan H; Ates F; Berber U; Saygin H; Sonmez G; Karademir K
Int Braz J Urol; 2016; 42(3):449-55. PubMed ID: 27286106
[TBL] [Abstract][Full Text] [Related]
35. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.
Hansen J; Auprich M; Ahyai SA; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Fisch M; Abbou CC; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Pummer K; Graefen M; Haese A; Walz J; Briganti A; Shariat SF; Chun FK
Eur Urol; 2013 Feb; 63(2):201-9. PubMed ID: 22854248
[TBL] [Abstract][Full Text] [Related]
36. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study.
Lin DW; Newcomb LF; Brown EC; Brooks JD; Carroll PR; Feng Z; Gleave ME; Lance RS; Sanda MG; Thompson IM; Wei JT; Nelson PS;
Clin Cancer Res; 2013 May; 19(9):2442-50. PubMed ID: 23515404
[TBL] [Abstract][Full Text] [Related]
37. PCA3 score accuracy in diagnosing prostate cancer at repeat biopsy: our experience in 177 patients.
Barbera M; Pepe P; Paola Q; Aragona F
Arch Ital Urol Androl; 2012 Dec; 84(4):227-9. PubMed ID: 23427750
[TBL] [Abstract][Full Text] [Related]
38. Prostate cancer antigen-3 (PCA3) and PCA3-based nomograms in the diagnosis of prostate cancer: an external validation of Hansen's nomogram on a Norwegian cohort.
Nygård Y; Haukaas SA; Eide GE; Halvorsen OJ; Gravdal K; Frugård J; Akslen LA; Beisland C
Scand J Urol; 2015 Feb; 49(1):8-15. PubMed ID: 25141128
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy.
Ochiai A; Okihara K; Kamoi K; Iwata T; Kawauchi A; Miki T; Fors Z
Int J Urol; 2011 Mar; 18(3):200-5. PubMed ID: 21332814
[TBL] [Abstract][Full Text] [Related]
40. Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer.
Cani AK; Hu K; Liu CJ; Siddiqui J; Zheng Y; Han S; Nallandhighal S; Hovelson DH; Xiao L; Pham T; Eyrich NW; Zheng H; Vince R; Tosoian JJ; Palapattu GS; Morgan TM; Wei JT; Udager AM; Chinnaiyan AM; Tomlins SA; Salami SS
Eur Urol Oncol; 2022 Aug; 5(4):430-439. PubMed ID: 33812851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
